Profile: Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacture and commercialization of important medicines for patients with cancer and other life-threatening conditions. Our marketed products include oncaspar®, depocyt®, abelcet® and adagen®. Our company engages in contract manufacturing for several pharmaceutical companies. We develop therapies through a variety of advanced technologies. Locked nucleic acid (LNA) technology is based on locked nucleic acid, a synthetic and similar form of RNA which is fixed in the helical shape adopted by RNA. When the LNA is incorporated into a short chain of nucleic acids (DNA and RNA are long chain nucleic acids), the presence of that LNA is therapeutically advantageous. The LNA is traditionally more stable than RNA and drugs containing LNAs have a very high binding affinity for RNA & subsequently increased metabolic stability. These potent drugs can then block the function of specific RNAs within cells and tissues possibly providing improved efficacy at lower doses than comparable drugs based on different chemistry. In particular, RNA antagonists comprised of LNAs can be used to switch off the synthesis of harmful proteins, thereby potentially altering disease outcomes in cancer or other serious disorders.